Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025

COMPASS Pathways plc

2024-FY EPS reported -$2.30

Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.
Cash and cash equivalents $165.1M at Dec 31, 2024; additional $140.4M net raised in Q1 2025.
Phase 3 COMP005 top-line 6-week data for TRD on track for Q2 2025; COMP006 26-week data expected H2 2026.
R&D expenses rose to $119.0M from $87.5M, driven by phase 3 trials and strategic reorganization costs.
Steve Levine, M.D., appointed Chief Patient Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.